Goldman Sachs Starts Pharmacyclics (PCYC) at Neutral

May 7, 2013 7:43 AM EDT Send to a Friend
Get Alerts PCYC Hot Sheet
Price: $131.45 -1.42%

Rating Summary:
    15 Buy, 9 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 51
Trade PCYC Now!
Join SI Premium – FREE
Goldman Sachs initiates coverage on Pharmacyclics (NASDAQ: PCYC) with a Neutral rating and $80 price target.

Despite ever-increasing competition, the firm sees peak ibrutinib sales of approx. $6 billion. However, the firm said this opportunity is reflected in the share price.

For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.

Shares of Pharmacyclics closed at $76.54 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage

Related Entities

Goldman Sachs

Add Your Comment